Details for Patent: 8,758,813
✉ Email this page to a colleague
Which drugs does patent 8,758,813 protect, and when does it expire?
Patent 8,758,813 protects XTAMPZA ER and is included in one NDA.
This patent has twenty-three patent family members in thirteen countries.
Summary for Patent: 8,758,813
Title: | Abuse-deterrent drug formulations |
Abstract: | An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion. |
Inventor(s): | Hirsh; Jane (Wellesley, MA), Fleming; Alison (Mansfield, MA), Rariy; Roman (Philadelphia, PA), Klibanov; Alexander M. (Boston, MA) |
Assignee: | Collegium Pharmaceutical, Inc. (Canton, MA) |
Application Number: | 13/870,690 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,758,813 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 8,758,813
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-001 | Apr 26, 2016 | RX | Yes | No | 8,758,813 | ⤷ Subscribe | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Subscribe | ||||
Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-002 | Apr 26, 2016 | RX | Yes | No | 8,758,813 | ⤷ Subscribe | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Subscribe | ||||
Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-003 | Apr 26, 2016 | RX | Yes | No | 8,758,813 | ⤷ Subscribe | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Subscribe | ||||
Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-004 | Apr 26, 2016 | RX | Yes | No | 8,758,813 | ⤷ Subscribe | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Subscribe | ||||
Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-005 | Apr 26, 2016 | RX | Yes | Yes | 8,758,813 | ⤷ Subscribe | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,758,813
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2003247876 | ⤷ Subscribe | |||
Canada | 2491572 | ⤷ Subscribe | |||
Canada | 2569958 | ⤷ Subscribe | |||
Canada | 2916869 | ⤷ Subscribe | |||
Cyprus | 1119831 | ⤷ Subscribe | |||
Denmark | 1765292 | ⤷ Subscribe | |||
European Patent Office | 1594467 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |